Format

Send to

Choose Destination
Am J Geriatr Psychiatry. 2014 Nov;22(11):1140-8. doi: 10.1016/j.jagp.2013.02.012. Epub 2013 Aug 20.

SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.

Author information

1
Geriatric Psychiatry Clinic, Mental Health Service Line, Minneapolis VA Medical Center, University of Minnesota Medical School, Minneapolis, MN. Electronic address: paulo.shiroma@va.gov.
2
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.
3
Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.

Abstract

OBJECTIVE:

Age at onset of first major depressive episode (MDE) does not necessarily translate into different treatment outcomes to antidepressants in late-life depression. The influence of genetic variants may affect this relationship.

DESIGN:

Post hoc data set analysis of the association between variants in the promoter region (indel, rs25531) and within intron 2 (Stin2 VNTR) of the SCL6A4 gene and treatment outcomes among older participants in the first treatment arm of the Sequenced Treatment Alternatives to Relieve Depression trial (STAR*D).

SETTING:

Participants were enrolled from 23 psychiatric and 18 primary care settings.

PARTICIPANTS:

Two hundred twenty-one, white non-Hispanic subjects, aged 60 to 75 years, with 16-item Quick Inventory of Depressive Symptomatology-Clinician Rating (QIDS-CR16) initial score ≥10, and who remained in the study for at least 6 weeks, were genotyped.

INTERVENTION:

Citalopram treatment for up to 14 weeks.

MEASUREMENTS:

Main outcome was remission rate defined as a score of ≤5 on the QIDS-CR16. Response was a secondary outcome defined as a reduction of ≥50% of baseline QIDS-CR16.

RESULTS:

Polymorphism in the indel promoter region was associated with remission among subjects whose first lifetime episode of major depression occurred later than age 55. In this group, subjects with L/L genotype had significantly higher remission (80% versus 43%) compared to those subjects with any other indel promoter genotype. Multivariate analysis demonstrated that the genetic effect of the indel promoter region on remission increases along with age at onset of MDE.

CONCLUSIONS:

Variants in the indel promoter region of the SLC6A4 gene have a more robust effect to antidepressant outcome among older subjects who experienced their first MDE at a later age. The mechanism of action of these variants remains to be determined.

KEYWORDS:

Depression; SLC6A4; Sequenced Treatment Alternatives to Relieve Depression (STAR*D); citalopram

PMID:
23973251
PMCID:
PMC4358736
DOI:
10.1016/j.jagp.2013.02.012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center